Plumber, S. A., Tate, T., Al-Ahmadie, H., Chen, X., Choi, W., Basar, M., Lu, C., Viny, A., Batourina, E., Li, J., Gretarsson, K., Alija, B., Molotkov, A., Wiessner, G., Lee, B. H. L., McKiernan, J., McConkey, D. J., Dinney, C., Czerniak, B., & Mendelsohn, C. L. (2024). Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-50678-2
Subjects:
Urinary Bladder Neoplasms
(MeSH)
Pyridones
(MeSH)
Pyrimidinones
(MeSH)
Rosiglitazone
(MeSH)
Disease Models, Animal
(MeSH)
Apoptosis
(MeSH)
Cell Proliferation
(MeSH)
Diagnosis and Treatment of Bladder Cancer
(OpenAlex Topic)
Lipid Metabolism in Cancer Pathogenesis
(OpenAlex Topic)
Peroxisome Proliferator-Activated Receptors
(OpenAlex Topic)
Publication Type:
Article
Unique ID:
10.1038/s41467-024-50678-2
PMID:
Journal:
Publication Date:
Data Source:
OpenAlex